本次会议是否有被否决议案：无 一、 会议召开和出席情况 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 百奥泰生物制药股份有限公司 证券代码：688177 证券简称：百奥泰 公告编号：2025-064 （一） 股东会召开的时间：2025 年 09 月 15 日 （二） 股东会召开的地点：广州市国际生物岛螺旋二路 18 号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 86 | | --- | --- | | 普通股股东人数 | 86 | | 2、出席会议的股东所持有的表决权数量 | 314,143,855 | | 普通股股东所持有表决权数量 | 314,143,855 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 75.8655 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 75.8655 | （四） 表决方式是 ...

Investment Rating - The industry rating is "Positive" for the next 12 months, expecting a growth rate exceeding 10% relative to the CSI 300 index [67][79]. Core Insights - The report highlights the impressive research outcomes of Chinese pharmaceutical companies showcased at the 2025 World Lung Cancer Conference (WCLC), emphasizing the strength of innovation in the sector. It also notes that Heng Rui has further advanced its overseas licensing strategy through the NewCo model [9][67]. - The report suggests continuous monitoring of the R&D progress of Chinese pharmaceutical companies, particularly in innovative drugs and related industrial chains, benefiting from optimized procurement rules in the pharmaceutical and medical device sectors, as well as the recovery of traditional Chinese medicine and medical services due to domestic demand [9][67]. Industry News - Bai Li Tian Heng's dual-target ADC for EGFR/HER3 has shown promising results at WCLC, with a 100% overall response rate in a study involving 154 patients [18]. - BeiGene presented the latest findings from its RATIONALE studies at WCLC, demonstrating significant survival benefits for its drug in treating non-small cell lung cancer [19]. - Kangfang Biotech updated data from its HARMONi study, showing improved overall survival rates, particularly in North America [20]. Company Announcements - Heng Rui Pharma signed a licensing agreement with Braveheart Bio for the HRS-1893 project, with an upfront payment of $65 million and potential milestone payments totaling up to $1.013 billion [35]. - The new drug application for KN026 by CSPC has been accepted by the National Medical Products Administration (NMPA) [39]. - Junshi Biosciences reported positive results from its Phase III clinical trial for an anti-IL-17A monoclonal antibody [40]. Market Review - The Shanghai Composite Index rose by 2.91%, while the Shenzhen Component Index increased by 7.11%. The pharmaceutical and biological sector saw a 1.76% increase, with most sub-sectors showing positive performance [53][57]. - As of September 11, 2025, the TTM P/E ratio for the pharmaceutical and biological industry was 31.56, with a valuation premium of 148% relative to the CSI 300 [57]. Weekly Strategy - The report recommends focusing on investment opportunities in innovative drugs and medical devices, as well as sectors benefiting from domestic demand recovery, while maintaining a "Positive" industry rating [67].

Group 1 - Yishitong plans to repurchase shares worth between 30 million to 55 million yuan at a price not exceeding 40.69 yuan per share, intended for employee stock ownership plans or equity incentives [1] - Guoyao Modern's subsidiary has received approval for a sodium bicarbonate injection to increase specifications and pass consistency evaluation [2] - Xinjing plans to reduce its shareholding by up to 1.2 million shares, accounting for 0.78% of the total share capital, between October 14, 2025, and January 13, 2026 [2] Group 2 - Jinfeikeda intends to apply for an additional credit limit of up to 60 million yuan from Jiangsu Financial Leasing [3] - Boshi Co. signed a project contract worth 235 million yuan with Guoneng Yulin Chemical for a three-year service period starting from October 31, 2025 [4] - Luan Energy reported a coal sales volume of 3.78 million tons in August, a decrease of 13.70% year-on-year [6] Group 3 - Shengnong Development achieved sales revenue of 1.857 billion yuan in August, a year-on-year increase of 19.11% [8] - Huading Co. plans to transfer 9.26% of its shares through public solicitation of transferees [10] - China Metallurgical Group's new contract amount from January to August decreased by 18.2% year-on-year, totaling 679.57 billion yuan [12] Group 4 - Longjing Environmental plans to invest approximately 3.99 billion yuan in the construction of a hydropower station project in the Democratic Republic of the Congo [14] - Longjing Environmental also plans to invest 2.391 billion yuan in an integrated energy station project, expected to be operational by the second quarter of 2026 [15] - Transsion Holdings has set the transfer price for its shares at 81.81 yuan per share, with a subscription rate of 1.15 times [17] Group 5 - Sinopec Oilfield Services won a bid for a natural gas pipeline project with a contract value of 858 million yuan [18] - Huaitian Thermal Power received a warning letter from the Liaoning Securities Regulatory Bureau for information disclosure violations [20] - China Nuclear Engineering signed new contracts totaling 96.633 billion yuan as of August [22] Group 6 - Shanghai Mechanical plans to publicly transfer 67% of its stake in Simic Welding Materials, with an estimated value of 291 million yuan [24] - Zhongke Environmental appointed Tang Xia as the new deputy general manager [26] - Baiyang Pharmaceutical signed a strategic cooperation agreement with Jikun Pharmaceutical for a drug project [28] Group 7 - Jinsong New Materials received a warning letter from the Zhejiang Securities Regulatory Bureau for fundraising irregularities [27] - Weitang Industrial obtained a national invention patent for a battery tray welding deformation control device [29] - Dongsoft Carrier secured two national invention patents related to energy management and voltage regulation circuits [30] Group 8 - Lian De Equipment won a bid for the BOE AMOLED production line project with a total amount of 201 million yuan [31] - Jingjiawei signed a strategic cooperation agreement with Anchaoyun to develop high-performance cloud desktop solutions [32] - Chuaning Biological received approval for a 1 billion yuan medium-term note registration [34] Group 9 - Jifeng Co. plans to reduce its shareholding by up to 2% through block trading [36] - Taihe Intelligent plans to transfer 5.79% of its shares to Sunshine New Energy Development Co., Ltd. [36] - Yangmei Chemical will change its stock name to "Luhua Technology" starting September 17, 2025 [38] Group 10 - ST Songfa's subsidiary signed contracts for the construction of four container ships, with a total value of approximately 300 to 500 million USD [40] - Green Energy Huichong plans to establish a joint venture with Xianyang Economic Development Group with a registered capital of 250 million yuan [42] - Baiyao Tai received a milestone payment of 5.4 million USD from Intas Pharmaceuticals [38]

Group 1 - Douyin E-commerce has launched a special governance initiative to combat the sale of low-value goods at high prices, resulting in the removal and banning of 23,000 related products and the handling of 41 merchants since the initiative began in September [1] - China Huaneng Group has established Huachuang Green Energy Technology Co., Ltd., with a registered capital of 20 million RMB, focusing on emerging energy technology research and services, including energy storage [2] - WeRide has successfully launched its autonomous minibus, Robobus, in Leuven, Belgium, marking its entry into the eleventh global market and further expanding its European operations [3] Group 2 - Anta Group announced plans to open 1,000 stores in Southeast Asia over the next three years, with a projected near doubling of business revenue in the region by the first half of 2025 [4] - Baotai has received a milestone payment of $5.4 million from Intas Pharmaceuticals for the commercialization rights of its product BAT2506 in the U.S. market [5] - Citigroup has upgraded Oracle's stock rating from neutral to buy, raising the target price from $240 to $410, indicating a potential 25% upside [6] Group 3 - China Shipbuilding has completed the share swap merger with China Shipbuilding Industry Corporation, with 3.053 billion new shares to be listed on September 16, 2025 [7] - Wuxi Guolian Tongzhi Technology Industry Investment Partnership has been established with a total investment of 1.22 billion RMB, focusing on venture capital and investment activities [8] - Kodiak Robotics has delivered its first factory-produced autonomous truck, which has been modified for use by Roush Industries [9] Group 4 - Shanghai has registered nine new generative AI services, bringing the total to 114 registered services as of September 11 [10] - BOE Technology has indicated pressure on TV prices and is considering appropriate maintenance plans based on market demand [11] - Alaska Airlines Group announced that Diana Birkett Rakow will become the CEO of Hawaiian Airlines starting October 29 [12] Group 5 - Goldman Sachs CEO David Solomon stated that the firm is expecting its busiest IPO week in over four years, following the recent listing of Klarna [11] - ANZ Bank's Chief Risk Officer Kevin Corbally has stepped down but will remain with the bank in a new role [13] - Alibaba's Quark has responded to issues faced by international students in completing identity verification for its education program, stating that it will optimize the process [14] Group 6 - Saudi Aramco has requested Asian buyers to increase their crude oil lifting volumes for October, following a recent price reduction [14] - Guangdong Province has introduced 23 measures to accelerate the high-quality development of inbound tourism, including optimizing visa policies and enhancing service levels [14]

Group 1: Resumption of Trading - Chip Origin Co., Ltd. plans to acquire equity in Chip Lai Zhi Rong Semiconductor Technology and raise matching funds, with stock resuming trading on September 12; simultaneously, new orders amounting to 1.205 billion yuan were signed, representing a year-on-year increase of 85.88%, setting a historical high for new orders [1] Group 2: Equity Transfers, Increases, Buybacks, and Reductions - Sunshine New Energy acquired 5.79% of Taihe Intelligent's shares, increasing its holding to 22.90% [1] - Transsion Holdings' shareholders plan to transfer 2.00% of their shares through inquiry [2] - Daye Intelligent's actual controller intends to transfer 8% of shares to Zhongsheng Zhengying Management's fund at a price of 6.75 yuan per share [2] - China Railway Industry's shareholders holding over 5% are transferring shares internally among concerted actors [2] - Baicheng Pharmaceutical raised the upper limit for share buyback to 80 yuan [3] - Shanghai Yizhong's actual controller proposed a share buyback of 30 to 35 million yuan [3] - Shengke Communication's National Integrated Circuit Industry Investment Fund has reduced its holdings by 4.1 million shares [4] Group 3: Daily Operations and External Investments - China Shipbuilding completed a stock swap merger with China Shipbuilding Industry Corporation, with new shares listed on September 16 [4] - Yangmei Chemical's stock name will change to "Luhua Technology" on September 17, 2025 [4] - Haixia Environmental Protection plans to sign a photovoltaic microgrid energy management contract with related parties [5] - Anning Co., Ltd. intends to participate in the substantial merger and restructuring of Jingzhi Minerals and its related enterprises through a phased cash payment of 6.508 billion yuan [6] - Baiotai signed a licensing and commercialization agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) injection, receiving a milestone payment of 5.4 million USD [6] - Aike Technology plans to issue convertible bonds to raise no more than 310 million yuan for new intelligent equipment industrialization projects, technological upgrades for Fuyang intelligent cutting equipment production lines, and to supplement working capital [6] - Tianfu Communication will distribute 5 yuan for every 10 shares for the first half of 2025, with the share registration date on September 18 [7] - Shoukai Co., Ltd.'s subsidiary Yinxin Company indirectly holds approximately 0.3% of Yushu Technology's equity, indicating a very low holding ratio [7]

百奥泰生物制药股份有限公司 自愿披露关于与 Intas Pharmaceuticals Ltd.就 BAT2506（戈利木单抗）注射液签署授权许可与商 业化协议收到里程碑付款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2025 年 2 月 26 日召开 2025 年第一次临时股东大会，会议表决通过 了《关于就 BAT2506（戈利木单抗）签署授权许可与商业化协议的议案》，该协 议于当日起生效。 证券代码：688177 证券简称：百奥泰 公告编号：2025-062 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于北京时间 2025 年 2 月 10 日与 Intas Pharmaceuticals Ltd.（以下简称"Intas"）签署授权许可 与商业化协议，将公司的 BAT2506（戈利木单抗）注射液在美国市场的独占的产 品商业化权益有偿许可给 Intas（以下简称"协议"或"本协议"）。百奥泰将负责 研发、生产及商业化供应，Intas 将通过其美国子公司 Accord BioPharm ...

Core Viewpoint - The company announced the approval of a licensing and commercialization agreement for BAT2506 (Golimumab) during its first extraordinary general meeting of 2025, which will take effect immediately [1] Group 1: Financial Details - The company received a milestone payment of $5.4 million from Intas, after deducting $600,000 for corporate income tax, resulting in a net amount that will be further reduced by bank fees [1] - The total amount received in RMB is approximately 38.36 million, calculated using the exchange rate of 7.1034 RMB per USD as of September 11, 2025 [1] Group 2: Regulatory Status - As of the date of the announcement, the company has submitted applications for the marketing authorization of BAT2506 (Golimumab) to the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), all of which have been accepted [1]

Core Insights - The company has signed a licensing and commercialization agreement with Intas Pharmaceuticals Ltd. for the exclusive commercialization rights of BAT2506 (Golimumab) injection in the U.S. market [1] - The company received a milestone payment of $5.4 million from Intas, after deducting $600,000 for corporate income tax, resulting in a net amount of approximately RMB 38.36 million [1] - This payment will enhance the company's cash reserves, supporting future pipeline research and internationalization strategies [1]

Policy Developments - Tibet Medical Insurance Bureau issued a statement clarifying that it has not authorized any organization or individual to promote "commercial health insurance" products, urging the public to remain vigilant against fraud [1] - The State Council approved the "Medical and Health Strong Foundation Project Implementation Plan," emphasizing its significance in enhancing grassroots medical service capabilities and promoting health initiatives in China [2] Drug and Device Approvals - Baiyoutai announced that its Adalimumab injection (Qletli®) received marketing approval from the UK MHRA, expanding its overseas sales portfolio and potentially positively impacting long-term performance [3] - Zhixiang Jintai received clinical trial approval for its GR1803 injection for systemic lupus erythematosus, a dual-specific antibody drug targeting BCMA and CD3 [4] - Haili Biological's subsidiary received acceptance for a medical device registration application for a natural bone repair material, classified as a Class III medical device [5] - Xinlitai announced that its Enarodustat tablets received a drug registration certificate for treating anemia in chronic kidney disease patients undergoing dialysis [6] Capital Market Activities - Beijing Simu Ruike Pharmaceutical Technology Co., Ltd. received approval for its listing on the New Third Board, with projected revenues of 446 million yuan and 418 million yuan for 2023 and 2024, respectively [8] - Palin Bio announced a share transfer agreement with China Biologic, involving the transfer of approximately 200 million shares, representing 21.03% of the total share capital, for a total price of about 4.699 billion yuan [9] Industry Events - Aimeike reported that its REGEN company's new factory in South Korea is steadily increasing production since its launch [10] - Novo Nordisk announced a global restructuring plan involving the layoff of approximately 9,000 positions, about 11% of its workforce, aiming for annual cost savings of around 8 billion Danish kroner by 2026 [10] Public Sentiment Alerts - Amgen announced plans by shareholders to reduce their holdings by up to 6% of the company's shares, primarily due to personal funding needs [11] - Shutaishen reported that its major shareholder, Xiangtang Group, reduced its stake by 336,070 shares, decreasing its holding from 7.69% to 6.99% [12]

Policy Developments - The State Council approved the "Implementation Plan for Strengthening Basic Medical and Health Services," emphasizing the importance of enhancing grassroots medical service capabilities and promoting the Healthy China initiative [3] Drug and Medical Device Approvals - Baiotai announced that its Adalimumab injection (Qletli) received marketing approval from the UK's MHRA, expanding the company's overseas product offerings and potentially positively impacting long-term performance [5] - Zhixiang Jintai received clinical trial approval for its GR1803 injection for systemic lupus erythematosus, a dual-specific antibody drug targeting BCMA and CD3, which could treat B-cell mediated autoimmune diseases [6] - Haili Biological's subsidiary received acceptance for a Class III medical device registration application for natural bone repair materials [7] - Xinlitai obtained a drug registration certificate for Enarodustat tablets, aimed at treating anemia in chronic kidney disease patients undergoing dialysis [9] Market Movements - Beijing Simu Ruike Pharmaceutical Technology Co., Ltd. was approved for listing on the New Third Board, with projected revenues of 446 million yuan and 418 million yuan for 2023 and 2024 respectively [11] - Palin Bio announced a share transfer agreement with China Biologic, transferring approximately 200 million shares for about 4.699 billion yuan, representing 21.03% of the company's total shares [12] Industry Trends - Novo Nordisk announced a global workforce reduction of approximately 9,000 positions, about 11% of its total employees, as part of a restructuring plan aimed at achieving annual cost savings of around 8 billion Danish kroner by 2026 [15]